VALBIOTIS S.A. EO -,10

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, VALBIOTIS S.A. EO -,10 had revenue of €765K and net profit of -€3.37M

(EUR)	June 2026	YoY
Revenue	765K	-
Gross profit	-171K	-
Net profit	-3.37M	-
EBITDA	-4.69M	-

Fundamentals

Metric	Value
Market capitalization	€22.29M
Number of shares	35.49M
52-week high/low	€1.30 - €0.49
Dividends	No
Beta	-0.20
P/E ratio	-2.13
PEG ratio	-0.03
P/B ratio	3.21
P/S ratio	16.66

Company profile

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.